FLDM - フリュ―ダイム （Fluidigm Corporation） フリュ―ダイムFLDMのチャート
FLDMの企業情報
| symbol | FLDM |
|---|---|
| 会社名 | Fluidigm Corp (DE) （フリュ―ダイム） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 フリューダイム(Fluidigm Corporation)は同社のコアマイクロ流体およびマスサイトメトリー技術に基づいて、単一細胞の探索・分析、及びゲノミクスの産業応用に焦点を当てた技術と生命科学ツールを作成・製造・販売する。同社は、ライフサイエンス及びAg-Bio産業セグメントのライフサイエンスツールの開発・製造・商業化を行っている。その製品には、予備的機器、予備的分析機器、分析機器、統合された流体回路（IFC）、及びアッセイおよび試薬が含まれる。その準備ツールには、C1シングルセル自動準備システム、アクセスアレイシステム、JunoシステムとIFC、CallistoシステムとIFCが含まれる。同社の分析機器には、Biomark HDシステム、EP1システム、Helios / CyTOF 2システムがある。同社のアッセイ及び試薬には、Delta Gene及びSNPタイプアッセイ、及びアクセスアレイ標的特異的プライマーおよび標的化配列決定プレッププライマーが含まれる。 フリュ―ダイムは、米国のマイクロ液体システム製造業者。学術機関、臨床検査室、製薬会社、バイオテクノロジ―企業、農業バイオテクノロジ―企業向けに統合流体回路、分析試料、試薬などの設計、製造、販売を行う。おもな製品はBioMark HD system、C1 Single-Cell Auto Prep system、EP1 systemなど。 Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, the Company strives to increase the quality of life for all. |
| 本社所在地 | 7000 Shoreline Court Suite 100 South San Francisco CA 94080 USA |
| 代表者氏名 | Samuel D. Colella サミュエルD.コールレラ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-266-6000 |
| 設立年月日 | 36281 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2011年 |
| 従業員数 | 505人 |
| url | www.fluidigm.com |
| nasdaq_url | https://www.nasdaq.com/symbol/fldm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -29.21900 |
| 終値（lastsale） | 7.42 |
| 時価総額（marketcap） | 290593407.44 |
| 時価総額 | 時価総額（百万ドル） 294.11810 |
| 売上高 | 売上高（百万ドル） 104.16700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 420.45610 |
| 当期純利益 | 当期純利益（百万ドル） -55.88900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Fluidigm Corporation revenues increased 5% to $51.7M. Net loss decreased 14% to $29.5M. Revenues reflect Europe segment increase of 14% to $17.6M Asia-Pacific segment increase of 21% to $10.7M. Lower net loss reflects Selling general and administrative decrease of 13% to $37.8M (expense) Research and development decrease of 8% to $14.6M (expense). |
FLDMのテクニカル分析
FLDMのニュース
Fluidigm Corporation (NASDAQ: FLDM) Stock Price Forecast: $100 2021/11/06 11:30:00 Stocks Register
Fluidigm Corporation (NASDAQ:FLDM) shares, rose in value on Friday, 11/05/21, with the stock price down by -2.98% to the previous days close as strong demand from buyers drove the stock to $4.88. Actively observing the price movement in the last trading, the stock closed the session at $5.03, falling within a range of $4.7617 and Fluidigm Corporation (NASDAQ: FLDM) Stock Price Forecast: $100 Read More »
Reviewing Singular Genomics Systems (NASDAQ:OMIC) & Fluidigm (NASDAQ:FLDM) 2021/11/05 06:32:41 Dakota Financial News
Fluidigm (NASDAQ:FLDM) and Singular Genomics Systems (NASDAQ:OMIC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk. Earnings and Valuation This table compares Fluidigm and Singular Genomics Systems top-line revenue, earnings per []
Fluidigm (FLDM) to Release Quarterly Earnings on Monday 2021/11/01 09:56:42 Transcript Daily
Fluidigm (NASDAQ:FLDM) is scheduled to be releasing its earnings data after the market closes on Monday, November 8th. Fluidigm has set its FY 2021 guidance at EPS and its Q3 2021 guidance at EPS.Persons interested in registering for the companys earnings conference call can do so using this link. Fluidigm (NASDAQ:FLDM) last issued its quarterly []
Fluidigm Corporation (NASDAQ: FLDM) Could Slash -133.01% Soon 2021/10/30 12:00:00 Stocks Register
Fluidigm Corporation (NASDAQ:FLDM) price on Friday, October 29, rose 1.98% above its previous days close as an upside momentum from buyers pushed the stocks value to $5.15. A look at the stocks price movement, the close in the last trading session was $5.05, moving within a range at $5.05 and $5.18. The beta value (5-Year Fluidigm Corporation (NASDAQ: FLDM) Could Slash -133.01% Soon Read More »
Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results 2021/10/20 12:30:00 Intrado Digital Media
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the market.
Fluidigm Announces Collaboration Agreement with Karolinska Institutet to Accelerate Customer Adoption of New CyTOF XT 2021/09/28 12:30:00 Intrado Digital Media
Department of Womens and Childrens Health to Work with Fluidigm on CyTOF Research Applications, Product Development Department of Womens and Childrens Health to Work with Fluidigm on CyTOF Research Applications, Product Development
Genomics Market 2021 Research and Clinical Analysis -10X Genomics, Qiagen NV, Fluidigm Corporation, Johnson & Johnson Private Limited 2021/09/14 10:26:46 OpenPR
The Global Genomics Market Research Report 2021-2030 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts
Lab-on-a-chip and Microarrays (Biochip) Market 2021 Segments Analysis and Key Company Profiles | Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories Inc., GE Healthcare, Roche Holding AG, Fluidigm Corporation, Thermo Fisher Scientific, etc. 2021/09/11 05:10:56 OpenPR
Biochips are increasingly being used in the field of biomedical and biotechnological research. With the advancement of technology, there has been a rise in the adoption of biochips in proteomics, such as in microarrays. The advantages of protein biochips include
Tumor Genomics Market Thundering USD 56 Bn by 2021-28 with Bio-Rad Laboratories, Abbott, Agilent, Danaher, F. Hoffmann-La Roche, Fluidigm, General Electric Company, Illumina, Merck, Myriad Genetics, PerkinElmer, QIAGEN, Siemens, Thermo Fisher Scientific 2021/09/10 11:37:25 OpenPR
The Tumor Genomics Market is expected to reach a market size of USD 56.54 Billion, to register a CAGR of +12% by 2028. Tumor genomic assays (or tests) analyze a sample of a cancer tumor to see how active certain
Medical Microfluidic Devices Industry- Exclusive Market Research Report 2021-2027 | Future Developments | Latest Innovation | Top Companies 2021/07/17 03:36:01 Jumbo News
Get Free Sample PDF (including full TOC, Tables and Figures) of Medical Microfluidic Devices Market: https://www.reportsnreports.com/contacts/requestsample.aspx?name=4424155 #Key Players- Roche Abbott Fluidigm Corporation Johnson & Johnson Siemens Healthcare Agilent Bio-Rad Laboratories Market segment by Type: Polymer Glass Silicon Other Market segment by Application: []
Polymerase Chain Reaction (PCR) Technologies Market 2021 Is Booming Across the Global by Share, Size, Growth, Segments and Forecast to 2025 | Top Players Analysis- Fluidigm Corporation, Bio-Rad Laboratories Inc., Qiagen NV, SYGNIS Pharma AG, Hoffmann-La Roche Ltd. 2021/07/15 10:16:55 Tramways Monthly
Global Polymerase Chain Reaction (PCR) Technologies Market highlights the information about the dominant players industries and market, technologies, and abilities over the trends and the developments of the industries. After deep research and analysis by the experts, they also disclosed the data about the strong contenders contributing in the market growth and expansion and challenging []
Global Radio Frequency Front-End Module Market 2021 Anticipated to Grow at an Impressive Rate by 2027 with Top Key player Thermo Fisher Scientific,RainDance,Bio-Rad,Fluidigm,Formulatrix,Promega,JN Medsys,Stilla Technologies 2021/07/12 07:39:28 OpenPR
Radio Frequency Front-End Module Market is Projected to Showcase Significant Growth Up to 2027, SWOT Analysis, Covid-19 Analysis, Business Growth and Segmental Analysis Latest research on Global Radio Frequency Front-End Module Market report covers forecast and analysis on a worldwide, regional
Global Microfluidic Chips Market 2026 Business Growth | AgilentFluidigm Corporation 2021/07/09 02:49:22 Jumbo News
LP INFORMATION recently released a research report on the Microfluidic Chips analysis, which studies the Microfluidic Chips industry coverage, current market competitive status, and market outlook and forecast by 2026. Global Microfluidic Chips Market 2021-2026 Research Report categorizes the global Microfluidic Chips by key players, product type, applications and regions,etc. The report also covers the latest industry data, key []
Fluidigm Announces Conference Call and Webcast of Second Quarter 2021 Financial Results 2021/07/08 20:01:00 Intrado Digital Media
SOUTH SAN FRANCISCO, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the market.